安必平AI三类证预计2026年获批，股东拟减持1.61%股份

Core Insights - The company has several noteworthy events to watch in the coming months regarding its stock performance [1] Recent Events - The company's cervical cytology AI class III certification is expected to be approved between late March and early April 2026, which may provide a monetization opportunity for its AI-assisted diagnostic business [2] - Nanjing Qianjing Venture Capital Partnership announced on January 18, 2026, its plan to reduce its holdings by up to 1.61% of the company's total share capital, necessitating attention to the implementation progress [2] Company Status - The management expressed confidence in returning to positive growth and achieving net profit recovery in 2026, primarily based on business adjustments and AI initiatives [3] Policy Environment - The National Healthcare Security Administration's guideline released in December 2025 regarding the pricing of pathological medical services may stimulate demand for digital pathology tools, although specific pricing will require negotiations with local authorities [4] Stock Price Situation - Technical analysis indicates that the stock price has recently tested Fibonacci resistance levels, with overbought stochastic indicators suggesting a potential short-term bearish correction risk [5] Future Development - The company plans to launch new pathology AI products annually starting in 2028 to enhance its product line [6]